NANOCELLE “ISSUE OF ALLOWANCE” BY US PATENT OFFICE
06 oct. 2021 11h10 HE
|
Medlab Clinical Ltd
SYDNEY, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical LTD (ASX.MDC) is pleased to announce NanoCelle® the company’s proprietary delivery platform has been issued a “Notice of Allowance” by the...
F-star Therapeutics is Granted Composition of Matter Patent for its Novel Second Generation STING Agonist, SB 11285
10 août 2021 08h00 HE
|
F-star Therapeutics, Inc.
Patent protection in U.S. runs through 2037 CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a...
F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update
29 mars 2021 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
F-star Therapeutics to Present at Upcoming Investor Conferences
04 mars 2021 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
23 févr. 2021 08h00 HE
|
Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years LAWRENCEVILLE, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a...
CELSION CORPORATION ANNOUNCES $35 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
22 janv. 2021 08h40 HE
|
Celsion CORP
LAWRENCEVILLE, NJ, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional...
Immuron Travelers’ Diarrhea Market Update
12 oct. 2020 06h00 HE
|
Immuron Limited
Key Points Immuron’s IMM-124E IND Program recommencesUniformed Services University to recommence planned Travelers’ Diarrhea clinical studyCOVID-19 - Consultancy Agreement with Infectious Disease...
Celsion Corporation Reports Second Quarter 2020 Financial Results and Provides Business Update
14 août 2020 08h00 HE
|
Celsion CORP
Initiates Promising Phase II Study of GEN-1 in Advanced Ovarian Cancer Will Continue Following Patients in Phase III OPTIMA Study for Overall Survival;Data Maturity at Issue Conference Call...
Celsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection Program
23 avr. 2020 08h30 HE
|
Celsion CORP
Added Capital Strengthens Balance Sheet, Assures Cash Through Major Phase III OPTIMA Study Data Readout Events Sale of an Additional $2.0 Million of NOL’s Expected in the 4th Quarter of 2020 ...
The Next Generation of Innovative Immunotherapy Agents, Inflammasome Inhibitors, Will Be Addressed in Panel Discussion on Monday, Feb. 17, 2020, at 10 a.m. EST
10 janv. 2020 11h50 HE
|
Noble Capital Markets, Inc.
FORT LAUDERDALE, Fla., Jan. 10, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- Noble Capital Markets, Inc. (“Noble”) announced it has assembled a panel of scientists and experienced life science...